comparemela.com

Latest Breaking News On - Verrica pharmaceuticals price performance - Page 1 : comparemela.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states
Joe-bonaccorso
Institutional-investors-weigh-in-on-verrica-pharmaceuticals
Verrica-pharmaceuticals-price-performance
Needham-company
Geode-capital-management
Nasdaq
Verrica-pharmaceuticals-inc
Verrica-pharmaceuticals-company-profile
Perceptive-advisors-llc
Securities-exchange-commission
Verrica-pharmaceuticals

Verrica Pharmaceuticals (NASDAQ:VRCA) Price Target Raised to $14.00 at Royal Bank of Canada

Verrica Pharmaceuticals (NASDAQ:VRCA – Free Report) had its price objective lifted by Royal Bank of Canada from $11.00 to $14.00 in a research report released on Tuesday morning, Marketbeat reports. The brokerage currently has an outperform rating on the stock. Separately, Needham & Company LLC upgraded shares of Verrica Pharmaceuticals from a hold rating to […]

Canada
United-states
America
Ted-white
Christopherg-hayes
Insider-activity-at-verrica-pharmaceuticals
Nasdaq
Verrica-pharmaceuticals-inc
Verrica-pharmaceuticals
Needham-company
America-corp
Institutional-investors-weigh-in-on-verrica-pharmaceuticals

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Director Paul B. Manning Purchases 200,000 Shares

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Free Report) Director Paul B. Manning bought 200,000 shares of Verrica Pharmaceuticals stock in a transaction on Monday, July 24th. The stock was acquired at an average cost of $5.02 per share, for a total transaction of $1,004,000.00. Following the acquisition, the director now owns 7,851,128 shares in the […]

United-states
Paulb-manning
Verrica-pharmaceuticals-company-profile
Institutional-trading-of-verrica-pharmaceuticals
Kovitz-investment-group-partners
Capital-management
Tower-research-capital
Verrica-pharmaceuticals-inc
Nasdaq
Verrica-pharmaceuticals-price-performance
News-ratings-for-verrica-pharmaceuticals-daily

BML Capital Management LLC Makes New $3.05 Million Investment in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)

BML Capital Management LLC acquired a new position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Rating) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,110,605 shares of the company’s stock, valued at approximately $3,054,000. Verrica Pharmaceuticals accounts for approximately 2.9% of BML Capital Management […]

Canada
Bml-capital-management
Quarter-for-verrica-pharmaceuticals
Nasdaq
Capital-management
Verrica-pharmaceuticals-profile
Cubist-systematic-strategies
Verrica-pharmaceuticals-price-performance
Royal-bank
Verrica-pharmaceuticals
News-ratings-for-verrica-pharmaceuticals-daily

Verrica Pharmaceuticals Inc. to Post Q2 2023 Earnings of ($0.28) Per Share, Brookline Capital Management Forecasts (NASDAQ:VRCA)

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Rating) – Analysts at Brookline Capital Management lowered their Q2 2023 earnings estimates for shares of Verrica Pharmaceuticals in a report released on Tuesday, May 9th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings per share of ($0.28) for the quarter, down from […]

Canada
Verrica-pharmaceuticals
News-ratings-for-verrica-pharmaceuticals-daily
Institutional-trading-of-verrica-pharmaceuticals
Royal-bank
Verrica-pharmaceuticals-inc
Cubist-systematic-strategies
Virtu-financial
Nasdaq
Verrica-pharmaceuticals-price-performance
Jefferies-financial-group

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.